Payment overview · 2025
General Payments
$414.86
21 reported records · 8 companies
Healthcare provider profile · identity verified
Adil M Mohiuddin, M.D.
Allopathic & Osteopathic Physicians|General Practice · GREENSBURG, KY · NPI 1073065983
Verified facts
What the public records show
CMS Open Payments records show Adil M Mohiuddin, M.D. received $414.86 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.34 | 39.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $123.87 | 29.9% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.87 | 12.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.52 | 4.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.54 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.21 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.84 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.67 | 2.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $414.86 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $149.83 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.59 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $106.08 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.81 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.19 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.87 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.67 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 293 | 58 |
| Lisinopril | Lisinopril | 247 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 225 | 53 |
| Famotidine | Famotidine | 189 | 39 |
| Omeprazole | Omeprazole | 187 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 143 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 25 |
| Trazodone Hcl | Trazodone Hcl | 142 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 37 |
| Furosemide | Furosemide | 110 | 25 |
| Metformin Hcl | Metformin Hcl | 110 | 19 |
| Ezetimibe | Ezetimibe | 98 | 21 |
| Jardiance | Empagliflozin | 83 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 20 |
| Potassium Chloride | Potassium Chloride | 80 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 12 |
| Sertraline Hcl | Sertraline Hcl | 78 | 16 |
| Celecoxib | Celecoxib | 76 | 36 |
| Methylprednisolone | Methylprednisolone | 73 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 13 |
| Simvastatin | Simvastatin | 62 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Meloxicam | Meloxicam | 58 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | 13 |
| Farxiga | Dapagliflozin Propanediol | 52 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 34 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Azithromycin | Azithromycin | 47 | 45 |
| Metformin Hcl Er | Metformin Hcl | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Losartan Potassium | Losartan Potassium | 46 | 15 |
| Carvedilol | Carvedilol | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 18 |
| Allopurinol | Allopurinol | 38 | 11 |
| Meclizine Hcl | Meclizine Hcl | 36 | 16 |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Gabapentin | Gabapentin | 32 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 20 |
| Estradiol | Estradiol | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Prednisone | Prednisone | 19 | 17 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 16 |
| Eliquis | Apixaban | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $414.86 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error